Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Ryan D GentzlerDavid O RileyLinda W MartinPublished in: Current oncology reports (2020)
Several small studies support the safety and feasibility of neoadjuvant immunotherapy, noting similar perioperative rates of morbidity and mortality compared with historical controls. Data from several phase II trials have shown high rates of major pathologic response (MPR), though it is unclear if this will correlate with a survival benefit. Phase III trials of neoadjuvant immunotherapy alone or in combination with chemotherapy are ongoing. Neoadjuvant immunotherapy offers a promising treatment modality in earlier stage NSCLC patients. Results of ongoing phase II and phase III trials will be essential in determining how to best integrate this treatment modality in the future.
Keyphrases
- phase ii
- phase iii
- locally advanced
- open label
- clinical trial
- rectal cancer
- neoadjuvant chemotherapy
- lymph node
- placebo controlled
- squamous cell carcinoma
- double blind
- end stage renal disease
- small cell lung cancer
- ejection fraction
- type diabetes
- randomized controlled trial
- newly diagnosed
- electronic health record
- peritoneal dialysis
- skeletal muscle
- cardiac surgery
- metabolic syndrome
- study protocol